Quercetin and Immunity: From Antioxidant to Senolytic

← Back to articles

Quercetin is a flavonoid found in onions, apples, berries, and capers. It has been studied for decades as an antioxidant. Its more recent twist is in a different field: senolytic therapy, which selectively clears senescent (worn-out, dysfunctional) cells that accumulate with age and drive chronic inflammation. This dual identity — a familiar plant compound that also has senolytic activity in combination — has made quercetin one of the most studied flavonoids in both nutrition and aging research.

Immune Modulation Evidence

Quercetin’s effects on the immune system are modulatory rather than “boosting.” In cell and animal studies it inhibits NF-κB signaling, lowers production of pro-inflammatory cytokines (IL-6, TNF-α), and stabilizes mast cells (cutting histamine release). A 2010 community RCT (Heinz et al., Pharmacological Research; PMID 20478383) randomized 1,002 adults aged 18–85 to placebo, 500 mg/day, or 1,000 mg/day quercetin for 12 weeks and tracked upper respiratory tract infections (URTIs). The whole-cohort URTI rate was not significantly reduced. A pre-specified subgroup of subjects aged 40+ who self-rated as physically fit (n = 325) on 1,000 mg/day showed a 36% drop in URTI severity and a 31% drop in total sick days vs placebo. So the picture is "modulator with conditions," not "cold preventer."

Senolytic Properties

The breakthrough that pulled quercetin from flavonoid curiosity to aging-research focus came from Zhu et al. (Aging Cell, 2015; PMID 25754370). Their group at the Mayo Clinic showed that the combination of dasatinib (a leukemia drug) plus quercetin (D+Q) selectively kills senescent cells in vitro and in vivo. Senescent cells stop dividing but resist apoptosis, secreting a stew of inflammatory proteins (the senescence-associated secretory phenotype, or SASP) that drives age-related disease. In mouse models, intermittent D+Q improved physical function and extended healthspan. The first human pilot followed in 2019 (Justice et al., EBioMedicine; PMID 30616998): 14 patients with idiopathic pulmonary fibrosis received intermittent D+Q (dasatinib 100 mg/day, quercetin 1,250 mg/day, 3 days per week for 3 weeks) and showed clinically meaningful improvements in 6-minute walk distance, gait speed, and chair-stand time. The work is early but real.

The Zinc Ionophore Theory

During the COVID-19 pandemic, quercetin drew attention as a possible zinc ionophore — a molecule that helps move zinc into cells, which would in theory raise intracellular zinc and inhibit viral RNA-dependent RNA polymerase. Cell-culture work (e.g., Dabbagh-Bazarbachi et al., 2014) showed quercetin can act as a zinc ionophore in vitro. Translation to humans is a big leap: the larger clinical trials of quercetin ± zinc for COVID-19 prevention or treatment have been mixed and largely null. The mechanism is interesting; the clinical benefit is unproven.

Bioavailability and Dosing

Quercetin’s main limitation is poor oral bioavailability — only about 2–5% of an oral dose reaches the systemic circulation in active form due to fast metabolism, glucuronidation, and limited solubility. That is why effective trial doses are typically 500–1,000 mg/day, and why enhanced-absorption formulations (quercetin phytosome, quercetin with bromelain or vitamin C) exist. For the senolytic protocol, researchers use intermittent dosing (e.g., 3 consecutive days per month) rather than daily, on the principle that senolysis needs brief high exposure rather than sustained low levels. For everyday immune or antioxidant use, 500–1,000 mg/day with food — ideally an enhanced-absorption form — is the standard.